Onconano Medicine Inc.'s $11.7 million in series A money should let the company finish phase I trials with its imaging agent and bring a therapeutic candidate to IND-enabling studies, CEO Ravi Srinivasan told BioWorld, as the company works with a "phenomenon [that] has not been exploited so far, even though it's been well-known and well-established in the cancer field."